TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Instagram Outage Disrupts Thousands of U.S. Users 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
KINGSPORT, Tenn., Feb. 14, 2017 -- ITL Pharma, Inc. (ITL), a LIAS Research Company, today announced awarding of a United States Patent (US 9,526,701) titled: "Sustained Drug Release and Improved Product Stability Using Non-Covalent Particle Coating Methods." This "umbrella" patent provides a novel approach to drug delivery, allowing for extended product stability and controlled release of the API.
TriThroid® (T3, Liothyronine, Na) is the lead product in the pipeline of products utilizing this technology. TriThroid®, now through Phase II clinical trials, provides for once-per-day dosing to fully replace thyroxine (T4) based products and is projected to be especially effective in hypothyroid patients that cannot effectively convert T4 to T3, by providing the active hormone (T3) directly to thyroid hormone target tissues.
"This new Patent is a significant break-through in providing shelf-stable products with sustained drug release and pH dependent PK profiles,” said Dr. Keith R. Latham, ITL's Chief Executive Officer. "This new Patent also provides a critical advance in the delivery of additional drugs in our pipeline including treatments for Cancer, Thyroid, Parkinson's, Alzheimer's and Inflammatory Diseases."
About ITL Pharma
ITL Pharma, Inc. is a privately held US Pharmaceutical company headquartered in Kingsport, Tennessee. Established in VA in 1996 by merger of Inovar Chemicals, Innovative Technologies and Technology Resources, ITL now focuses on new drug discovery and development with 22 new pipeline drugs in 8 therapeutic arenas (www.ITLPharmaceuticals.com).
ITL has now completed Phase II clinical trials on TriThroid®, a sustained release, sustained effects, once-per-day dosing product containing Liothyronine (T3) as the API. This prescription product will replace Levothyroxine (T4) products in a $3.4 Billion market. ITL's vertical integration program anticipates Partnering with companies specializing in market launch and World-Wide distribution and sales.
About LIAS Research
Latham Institute of Advanced Science (LIAS), the parent company for ITL Pharma, provides program integration and management resources to the LIAS Family of Companies. LIAS companies have a pipeline of new prescription drugs and marketed Over the Counter (OTC) products. LIAS CEO, Gina Garland, stated: “We are very pleased with the outstanding progress ITL has made in the treatment of hypothyroidism and other diseases.”
Contact: Dr. Keith R. Latham, CEO ITL Pharma, Inc. 423-444-1474: [email protected]
